AR116937A1 - Anticuerpo monoclonal que se une específicamente al antígeno cd20 - Google Patents
Anticuerpo monoclonal que se une específicamente al antígeno cd20Info
- Publication number
- AR116937A1 AR116937A1 ARP190103167A ARP190103167A AR116937A1 AR 116937 A1 AR116937 A1 AR 116937A1 AR P190103167 A ARP190103167 A AR P190103167A AR P190103167 A ARP190103167 A AR P190103167A AR 116937 A1 AR116937 A1 AR 116937A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- antibody
- binding fragment
- seq
- nucleic acid
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 10
- 102000036639 antigens Human genes 0.000 title abstract 10
- 108091007433 antigens Proteins 0.000 title abstract 10
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 title abstract 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 title abstract 4
- 239000012634 fragment Substances 0.000 abstract 8
- 238000000034 method Methods 0.000 abstract 4
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente se refiere a la biotecnología y proporciona un anticuerpo monoclonal que se une específicamente al antígeno CD20. La presente también se refiere a ADN que codifica dicho anticuerpo, los correspondientes vectores de expresión y métodos para su producción, al igual que métodos de tratamiento para emplear dicho anticuerpo. Reivindicación 1: Un anticuerpo monoclonal o fragmento de unión al antígeno de este que se une específicamente a CD20 que comprende: a) un dominio variable de la cadena pesada que comprende una secuencia de aminoácidos que se muestra en la SEQ ID Nº 2 o SEQ ID Nº 6; b) un dominio variable de la cadena ligera que comprende una secuencia de aminoácidos que se muestra en la SEQ ID Nº 4 o SEQ ID Nº 8. Reivindicación 10: Un ácido nucleico que codifica un anticuerpo o fragmento de unión al antígeno de este según cualquiera de las reivindicaciones 1 - 9. Reivindicación 12: Un vector de expresión que comprende un ácido nucleico según cualquiera de las reivindicaciones 10 - 11. Reivindicación 13: Un método para la producción de una célula hospedante para producir un anticuerpo o fragmento de unión al antígeno de este según cualquiera de las reivindicaciones 1 - 9 que comprende la transformación de una célula con un vector según la reivindicación 12. Reivindicación 14: Una célula hospedante para producir un anticuerpo o fragmento de unión al antígeno de este según cualquiera de las reivindicaciones 1 - 9, que comprende un ácido nucleico según cualquiera de las reivindicaciones 10 - 11. Reivindicación 15: Un método para la producción de un anticuerpo o fragmento de unión al antígeno de este según cualquiera de las reivindicaciones 1 - 9, que comprende cultivar una célula hospedante según la reivindicación 14 en un medio de cultivo en condiciones suficientes para producir dicho anticuerpo o fragmento de unión al antígeno de este, si es necesario, seguido del aislamiento y la purificación del anticuerpo producido o de un fragmento de unión al antígeno de este. Reivindicación 16: Una composición farmacéutica para la profilaxis o el tratamiento de una enfermedad o un trastorno mediado por CD20, que comprende un anticuerpo o fragmento de unión al antígeno de este según cualquiera de las reivindicaciones 1 - 9 en combinación con uno o más excipientes farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2018138510A RU2724469C2 (ru) | 2018-10-31 | 2018-10-31 | Моноклональное антитело, которое специфически связывается с cd20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR116937A1 true AR116937A1 (es) | 2021-06-30 |
Family
ID=70462324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103167A AR116937A1 (es) | 2018-10-31 | 2019-10-31 | Anticuerpo monoclonal que se une específicamente al antígeno cd20 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US12202906B2 (es) |
| EP (1) | EP3875486A4 (es) |
| JP (1) | JP7654541B2 (es) |
| KR (1) | KR20210084604A (es) |
| CN (1) | CN113272329B (es) |
| AR (1) | AR116937A1 (es) |
| AU (1) | AU2019373999A1 (es) |
| BR (1) | BR112021008326A2 (es) |
| CA (1) | CA3117486A1 (es) |
| CL (1) | CL2021001104A1 (es) |
| CO (1) | CO2021005178A2 (es) |
| EA (1) | EA202191173A1 (es) |
| EC (1) | ECSP21028958A (es) |
| IL (1) | IL282742B1 (es) |
| JO (1) | JOP20210100A1 (es) |
| MA (1) | MA53186B2 (es) |
| MX (1) | MX2021005033A (es) |
| PE (1) | PE20211731A1 (es) |
| PH (1) | PH12021550991A1 (es) |
| RU (1) | RU2724469C2 (es) |
| SG (1) | SG11202104248UA (es) |
| TW (1) | TWI857982B (es) |
| UY (1) | UY38432A (es) |
| WO (1) | WO2020091634A1 (es) |
| ZA (1) | ZA202102874B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119997972A (zh) * | 2022-07-26 | 2025-05-13 | 拜奥卡德联合股份公司 | 抗cd20抗体的药物组合物及其用途 |
| CN121181703A (zh) * | 2025-11-25 | 2025-12-23 | 苏州大学附属儿童医院 | 一种抗cd20重组兔单克隆抗体及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
| US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| FI891226A7 (fi) | 1988-04-28 | 1989-10-29 | The Board Of Trustees Of The Leland | Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
| DK0463101T3 (da) | 1989-03-21 | 1994-03-14 | Immune Response Corp Inc | Vaccination og fremgangsmåde mod sygdomme, som skyldes patogene reaktioner og specifikke T-cellepopulationer |
| NZ234586A (en) | 1989-07-19 | 1993-02-25 | Arthur Allen Vandenbark | Peptide of a t-cell receptor capable of inducing protection from immune-related disease |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| EP1514934B1 (en) | 1992-02-06 | 2008-12-31 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| PL174494B1 (pl) | 1992-11-13 | 1998-08-31 | Idec Pharma Corp | Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| CN101914158A (zh) * | 2002-02-14 | 2010-12-15 | 免疫医疗公司 | 抗cd 20抗体及其融合蛋白和使用方法 |
| EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| AU2011226858B2 (en) * | 2002-12-16 | 2015-01-22 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| UA99933C2 (ru) | 2003-04-09 | 2012-10-25 | Дженентек, Инк. | Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа |
| DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| RU2489166C2 (ru) | 2006-04-09 | 2013-08-10 | Джинентех, Инк. | Применение антитела для лечения аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа |
| US9175086B2 (en) * | 2010-02-10 | 2015-11-03 | Immunogen, Inc. | CD20 antibodies and uses thereof |
| CN102167744B (zh) * | 2010-02-25 | 2014-08-20 | 上海百迈博制药有限公司 | 一种全人源抗cd20单克隆抗体、其制备方法及用途 |
| CN102190728B (zh) * | 2010-03-17 | 2014-07-02 | 永卓博济(上海)生物医药技术有限公司 | 一种人源化抗cd20单克隆抗体 |
| CN102875678B (zh) * | 2011-07-13 | 2014-08-06 | 无锡天演生物技术有限公司 | 全人源抗人cd20单抗分子及其应用 |
| GB201220242D0 (en) * | 2012-11-09 | 2012-12-26 | Fusion Antibodies Ltd | Antibody |
-
2018
- 2018-10-31 RU RU2018138510A patent/RU2724469C2/ru active
-
2019
- 2019-10-29 TW TW108139053A patent/TWI857982B/zh active
- 2019-10-30 WO PCT/RU2019/050205 patent/WO2020091634A1/ru not_active Ceased
- 2019-10-30 BR BR112021008326-0A patent/BR112021008326A2/pt unknown
- 2019-10-30 CA CA3117486A patent/CA3117486A1/en active Pending
- 2019-10-30 SG SG11202104248UA patent/SG11202104248UA/en unknown
- 2019-10-30 UY UY0001038432A patent/UY38432A/es unknown
- 2019-10-30 AU AU2019373999A patent/AU2019373999A1/en active Pending
- 2019-10-30 US US17/288,234 patent/US12202906B2/en active Active
- 2019-10-30 JO JOP/2021/0100A patent/JOP20210100A1/ar unknown
- 2019-10-30 CN CN201980087511.2A patent/CN113272329B/zh active Active
- 2019-10-30 JP JP2021523796A patent/JP7654541B2/ja active Active
- 2019-10-30 PE PE2021000556A patent/PE20211731A1/es unknown
- 2019-10-30 KR KR1020217016587A patent/KR20210084604A/ko not_active Ceased
- 2019-10-30 EA EA202191173A patent/EA202191173A1/ru unknown
- 2019-10-30 MA MA53186A patent/MA53186B2/fr unknown
- 2019-10-30 MX MX2021005033A patent/MX2021005033A/es unknown
- 2019-10-30 EP EP19880700.0A patent/EP3875486A4/en active Pending
- 2019-10-31 AR ARP190103167A patent/AR116937A1/es unknown
-
2021
- 2021-04-22 CO CONC2021/0005178A patent/CO2021005178A2/es unknown
- 2021-04-22 EC ECSENADI202128958A patent/ECSP21028958A/es unknown
- 2021-04-28 CL CL2021001104A patent/CL2021001104A1/es unknown
- 2021-04-28 IL IL282742A patent/IL282742B1/en unknown
- 2021-04-29 ZA ZA2021/02874A patent/ZA202102874B/en unknown
- 2021-04-30 PH PH12021550991A patent/PH12021550991A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126242A2 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
| EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| EA201992206A1 (ru) | Моноклональное антитело к pd-l1 | |
| ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
| PH12021550244A1 (en) | Anti-btla antibody | |
| CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| PE20230384A1 (es) | Anticuerpos cd163 o proteinas de union | |
| AR124084A1 (es) | ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO | |
| AR116937A1 (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
| EA202090864A1 (ru) | Моноклональное антитело к il-5r | |
| AR099604A1 (es) | Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso | |
| AR122286A1 (es) | Anticuerpos potenciadores del factor h y usos de estos | |
| MX2021014882A (es) | Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa. | |
| AR131856A1 (es) | Proteínas de unión a cd40 | |
| AR125219A1 (es) | Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo | |
| MX2021014885A (es) | Composiciones de anticuerpos anti-tnf, y métodos para el tratamiento de la artritis psoriásica. | |
| AR124906A1 (es) | Materiales y métodos para dirigirse a las células t reguladoras para potenciar la vigilancia inmunitaria | |
| AR133427A1 (es) | Anticuerpos anti-gprc5d y composiciones | |
| AR132043A1 (es) | Anticuerpos muc1 y métodos de uso | |
| AR132040A1 (es) | Anticuerpos muc1 y cd16a y métodos de uso | |
| AR121867A1 (es) | Anticuerpos monoclonales anti-sars-cov-2 | |
| MX2023007028A (es) | Composiciones de proteínas y métodos para producir y usar las mismas. | |
| ES2670405T3 (es) | Anticuerpos capaces de unirse específicamente a oligómeros de beta amiloides, y su utilización |